Sorafenib-microRNA combination therapy for liver cancer
AssigneeMirna Therapeutics, Inc.
InventorsAndreas Bader, Jane Zhao
Life of this patent
Estimating the term…
Abstract
A method of treating a subject having liver cancer can include administering a synthetic oligonucleotide to a subject having liver cancer, the oligonucleotide comprising a sequence that is at least 80% identical to at least one of SEQ ID NO:1-12 (e.g., a miR-34 or miR-215 mimic); and administering sorafenib to the subject, wherein the molar ratio of sorafenib:oligonucleotide administered to the subject is in the range of about 10-2000 (e.g., a ratio that provides a superior, for example synergistic or greater than additive, effect).
Claims19
A synergistic compound combination comprising a synergistically effective amount of:
- (a) sorafenib;
- and (b) a 17-30 basepair synthetic oligonucleotide comprising:
- (i) a guide strand comprising a sequence according to SEQ ID NO:9;
- (ii) a separate passenger strand that is at least 60% complementary to the guide strand;
- and
- (iii) a 5′ end nucleotide modification on the passenger strand, wherein the 5′ end nucleotide modification is:
- a 5′ end terminal nucleotide cap;
- a mismatch at the first nucleotide at the 5′ end of the passenger strand;
- a mismatch at the second nucleotide at the 5′ end of the passenger strand;
- or any combinations thereof.
Dependencies are inferred from the claim text.